Insider Transactions in Q3 2021 at Chinook Therapeutics, Inc. (KDNY)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 24
2021
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+11.53%
|
$0
$0.42 P/Share
|
|
Sep 24
2021
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
20,000
-13.04%
|
$260,000
$13.0 P/Share
|
|
Sep 20
2021
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
2,000
+1.79%
|
$24,000
$12.0 P/Share
|
|
Aug 27
2021
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
340,000
-10.79%
|
$4,760,000
$14.0 P/Share
|
|
Aug 27
2021
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
510,000
-10.78%
|
$7,140,000
$14.0 P/Share
|
|
Aug 27
2021
|
Davis Jerel Director |
SELL
Open market or private sale
|
Indirect |
850,000
-10.78%
|
$11,900,000
$14.0 P/Share
|
|
Aug 19
2021
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+2.71%
|
$36,000
$12.0 P/Share
|
|
Aug 18
2021
|
Srinivas Akkaraju Director |
BUY
Open market or private purchase
|
Indirect |
208,500
+5.82%
|
$2,293,500
$11.98 P/Share
|
|
Aug 18
2021
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
7,000
+6.26%
|
$77,000
$11.74 P/Share
|